GLP-1 Weight Loss: Cancer Risk Reduction Evidence
GLP-1 Clinical Relevance #51Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic Clinical TrialCohort StudyObesity-Related Cancer RiskGLP-1 Receptor…
GLP-1 Receptor Agonists and Breast Cancer Risk
GLP-1 Clinical Relevance #52Moderate Clinical Relevance Relevant context for GLP-1 prescribers; interpret with care. ⚕ GLP-1 News | CED Clinic Clinical TrialCohort StudyWeight LossSemaglutidePrimary CareAdults with ObesityCancer…
GLP-1 Receptor Agonist Safety: Optic Neuropathy Risk Data
This article reviews optic neuropathy risk linked to GLP-1 receptor agonists in type 2 diabetes. While the absolute risk is modest, awareness is essential for safe prescribing. Baseline ophthalmologic assessment is advised for high-risk patients.
GLP-1 Weight Loss: What Happens After You Stop Ozempic
GLP-1 discontinuation outcomes vary among patients after stopping Ozempic. Some maintain weight loss while others experience gradual weight regain. Understanding these outcomes helps guide realistic treatment expectations.
Cannabis Use Disorder Carries Greater Psychiatric Risk for Adolescents Than Adults, Study Finds
Cannabis use disorder adolescent psychiatry risks are significant and differ from those in adults. This study highlights elevated psychiatric risks in adolescents with cannabis use disorder. Understanding these risks is crucial for clinical care and…
GLP-1 Receptor Agonist Evidence in Metabolic Heart Risk
Metabolically healthy obesity carries a measurable increase in cardiovascular risk over 20 years. GLP-1 receptor agonist therapy addresses multiple cardiometabolic risk factors beyond metabolic panel results. Long-term monitoring and treatment are…
GLP-1 Clinical Evidence: Insulin Resistance in Childhood Obesity
Insulin resistance childhood obesity is a critical focus for early metabolic intervention. This article reviews GLP-1 clinical evidence supporting treatment strategies in pediatric patients. Understanding epigenetic markers helps guide therapy before…
Cannabis Use Linked to Increased Healthcare Burden in Cyclical Vomiting Syndrome
Cannabis hyperemesis syndrome risk is linked to increased healthcare utilization in patients with cyclical vomiting syndrome. This study highlights poorer outcomes associated with cannabis use in CVS. Understanding this risk is crucial for managing…
Association of Cannabis Use Disorder Versus Other Substance Use Disorders With Psychiatric Conditions: A Propensity-Matched Retrospective Cohort Analysis
This study examines the cannabis use disorder psychiatric risk profile compared to other substance use disorders. Findings indicate lower rates of schizophrenia, depression, and psychotic disorders in cannabis users. These insights inform clinical risk…
Associations Between Cannabis Use and Inflammatory Biomarkers Among People with HIV
This study investigates cannabis use inflammatory biomarkers among people with HIV to assess potential immune effects. Researchers analyzed 13 plasma biomarkers in 532 virally suppressed patients. Findings inform clinical discussions on cannabis use and…